An mRNA vaccine encoding five conserved Group A Streptococcus antigens

Nichaela Harbison-Price, Ismail Sebina, Rhiannon A. Bolton, Meredith Finn, Amanda J. Cork, Isabel G. Courtney, Steven Hancock, Ruby Pelingon, Johanna Richter, Olivia Ericsson, Shannon Green, Celeste Cuellar, Laura Davis, Brody Pullinger, Jack Na, Gayathiri Elangovan, David M. P. Oliveira, Bodie F. Curren, Nia Bickham, Miguel Aguirre, Christina Dold, Stephan Brouwer, Obadiah Plante, Gabrielle T. Belz and Mark J. Walker ()
Additional contact information
Nichaela Harbison-Price: The University of Queensland
Ismail Sebina: The University of Queensland
Rhiannon A. Bolton: The University of Queensland
Meredith Finn: 325 Binney Street
Amanda J. Cork: The University of Queensland
Isabel G. Courtney: The University of Queensland
Steven Hancock: The University of Queensland
Ruby Pelingon: The University of Queensland
Johanna Richter: The University of Queensland
Olivia Ericsson: 325 Binney Street
Shannon Green: 325 Binney Street
Celeste Cuellar: 325 Binney Street
Laura Davis: The University of Queensland
Brody Pullinger: The University of Queensland
Jack Na: The University of Queensland
Gayathiri Elangovan: The University of Queensland
David M. P. Oliveira: The University of Queensland
Bodie F. Curren: The University of Queensland
Nia Bickham: The University of Queensland
Miguel Aguirre: The University of Queensland
Christina Dold: 325 Binney Street
Stephan Brouwer: The University of Queensland
Obadiah Plante: 325 Binney Street
Gabrielle T. Belz: The University of Queensland
Mark J. Walker: The University of Queensland

Nature Communications, 2025, vol. 16, issue 1, 1-14

Abstract: Abstract A commercial vaccine to address the high global burden of Group A Streptococcus (GAS) disease is an urgent and unmet medical need. Messenger RNA (mRNA) lipid-nanoparticle (LNP) vaccines represent a largely untapped platform for targeting bacterial pathogens. Here, we evaluate the immunogenicity and preclinical efficacy of a multicomponent mRNA-LNP vaccine formulation based on the GAS vaccine, Combo#5. Combo#5 mRNA-LNP antigens confer protection from infection in mouse intraperitoneal and subcutaneous challenge models. Combo#5 mRNA-LNP vaccination generates significantly increased frequencies and numbers of effector type CD4+ and CD8 + T cells in the spleen, enhances T follicular helper cells, germinal center B cells and memory B cells in the spleen and draining lymph nodes, and boosts the production of antigen-specific antibodies. These findings demonstrate the potential of the mRNA-LNP platform for the development of vaccines against bacterial pathogens.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60580-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60580-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60580-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().